Omnicell (NASDAQ:OMCL) Issues Q4 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its fourth quarter earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $0.55-$0.62 for the period, compared to the consensus estimate of $0.47. The company issued revenue guidance of $295-$305 million, compared to the consensus revenue estimate of $287.85 million. Omnicell also updated its FY 2024 guidance to 1.650-1.720 EPS.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on OMCL shares. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 19th. Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and upped their price target for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. Benchmark reissued a “buy” rating and set a $48.00 target price on shares of Omnicell in a research note on Wednesday, October 9th. Bank of America raised their target price on Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, Wells Fargo & Company upped their price target on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research report on Monday, October 14th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $41.33.

Omnicell Stock Up 36.7 %

OMCL traded up $14.73 during midday trading on Wednesday, hitting $54.85. 901,511 shares of the company’s stock traded hands, compared to its average volume of 516,551. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22. The company has a market cap of $2.52 billion, a PE ratio of -113.13, a price-to-earnings-growth ratio of 43.55 and a beta of 0.83. Omnicell has a one year low of $25.12 and a one year high of $55.74. The stock’s fifty day simple moving average is $42.95 and its 200-day simple moving average is $34.95.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. During the same period in the prior year, the company posted $0.29 earnings per share. Omnicell’s revenue for the quarter was down 7.4% on a year-over-year basis. As a group, equities analysts anticipate that Omnicell will post 0.64 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.